First of all, the current development of microfluidic actuated and controlled technologies is summarized. In the microfluidic chip, micropumps which plays the role of transmission and distribution of fluid flow are mainly divided into two categories, the mechanical micropump (acting on some structure of the chip) and the non-mechanical micropumps (directly driving the fluid). Mechanical micropumps transfer and control microfluids by the mechanical moving parts, representatives of which are diaphragm micropump, piston micropump, planetary gear micropump, pneumatic micropump, electrical-related micropump, piezoelectric micropump, and optically driven micropump, simple in design and operation but limited by film deformation and brittleness, complex fabrication process, high cost, poor reliability, and difficult integration. Non-mechanical micropumps rely on various physical or chemical effects to convert some non-mechanical energy into kinetic energy to drive the fluid, representatives of which are electroosmotic micropump, magnetohydrodynamic micropump, bubble-type micropump, capillary… 

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has been approved by the NMPA to enter Phase II clinical trial as monotherapy or in combination with a PD-1 inhibitor for the treatment of triple-negative breast cancer (TNBC). The Phase II clinical trial recently approved aims to evaluate the efficacy and safety of 9MW2821 as monotherapy or in combination with a PD-1 inhibitor in patients with locally advanced or metastatic TNBC. The study includes two cohorts: Cohort A will enroll patients with locally advanced or metastatic TNBC who have previously received taxane/anthracycline-based chemotherapy and topoisomerase inhibitor based antibody-drug conjugate treatment, and will receive 9MW2821 monotherapy; Cohort B will enroll patients with locally advanced or metastatic TNBC who have not previously received systemic therapy, and will receive a combination treatment of… 

Forscher der Griffith University haben erstmals weltweit herausgefunden, dass die fehlerhafte Zellfunktion bei Veteranen, die am Golfkriegssyndrom (GWI) leiden, das auch als Golfkriegssyndrom (GWS) bekannt ist, wahrscheinlich auf die intensive Einwirkung gefährlicher biologischer und chemischer Kampfstoffe während des Kriegsdienstes zurückzuführen ist. Die bahnbrechende Forschung mit dem Titel „Neuartige Charakterisierung endogener Transient Receptor Potential Melastatin 3-Ionenkanäle von Teilnehmern des Golfkriegssyndroms“ wurde in PLOS ONE veröffentlicht . Sie löst ein Rätsel, das Medizinwissenschaftler jahrzehntelang vor Rätsel gestellt hat. Die vom National Center for Neuroimmunology and Emerging Diseases (NCNED) der Griffith University an der Gold Coast durchgeführte Untersuchung ergab, dass die für den Transport von Kalzium in die Zellen wichtigen Zellstrukturen, die sogenannten transienten Rezeptorpotential-Ionenkanäle, bei Veteranen mit GWI defekt sind. NCNED-Direktorin und Autorin Professor Sonya Marshall-Gradisnik sagte, dass die Rolle von Kalzium als Signalmolekül in Zellen von entscheidender Bedeutung sei, da es… 

Yarooms, der Entwickler von Arbeitsplatzsoftware, bringt eine Beta-Version von Yarvis auf den Markt, dem KI-gestützten Arbeitsplatzassistenten, der die Interaktion von Teams mit ihren Arbeitsplätzen revolutionieren soll. Yarvis verkörpert den neuesten Fortschritt im Bereich der künstlichen Intelligenz am Arbeitsplatz und verändert die Art und Weise, wie Teams mit ihrer Arbeitsumgebung umgehen. Er […] Yarooms bringt Yarvis auf den Markt, den KI-gesteuerten Arbeitsplatzassistenten

Today AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients. Omega3 lipids called polyunsaturated fatty acids (PUFAs) that are found in microscopic shrimp-like crustaceans called Krill from the waters around Antarctica are key to maintaining a low inflammatory state.  Some studies indicate that Krill contains Omega3 in an easily digested phospholipid form that may achieve more effective integration into cellular membranes compared with the triglyceride-rich form predominant in fish oil.  And the concentrated Superba Boost Krill Oil (AKBM-3031) was highly ranked by the hypothesis-based CoLTs (Combined Lupus Treatment Scoring) published approach for testing in the ORKIDS clinical trial.

Die ehemalige Intel-Führungskraft Claire Newman übernimmt die Stelle der neuen Geschäftsführerin des Children’s Cancer Therapy Development Institute. Das Children’s Cancer Therapy Development Institute (cc-TDI, www.cc-tdi.org)), ist eine gemeinnützige 501c3-Biotechnologieorganisation, deren Aufgabe darin besteht, wissenschaftliche Entdeckungen in klinische Tests umzusetzen, indem sie neue krankheitsspezifische Behandlungsmöglichkeiten für krebskranke Kinder erforscht und erprobt.

BD erklärte, dass die aufgrund von Lieferproblemen verringerte Verfügbarkeit von Flaschen für Blutkulturmedien das Unternehmen daran hindere, die weltweite Nachfrage zu decken. Eine Unterbrechung der Versorgung mit BD Bactec-Flaschen für Blutkulturmedien werde voraussichtlich Auswirkungen auf die Diagnose und die weitere Behandlung der Patienten haben, teilte die US-amerikanische Lebensmittelüberwachungs- und Arzneimittelzulassungsbehörde Food and Drug Administration am Mittwoch mit . BD teilte seinen Kunden im Juni mit, dass es in den kommenden Monaten zu „zeitweiligen Lieferverzögerungen“ kommen könne. Das Unternehmen gab an, dass die reduzierte Verfügbarkeit von Plastikflaschen bei seinem Lieferanten es daran hindere, Bactec so herzustellen, dass die gesamte weltweite Nachfrage gedeckt werden könne. Die FDA rät Laboren, „Strategien zu entwickeln, um die Verwendung von Flaschen für Blutkulturmedien nach klinischem Bedarf zu priorisieren, um die Qualität und Sicherheit der Patientenversorgung aufrechtzuerhalten.“ Am Mittwoch setzte die Behörde Flaschen für Blutkulturmedien auf die… 

Private Health Management („PHM“), a clinically sophisticated complex care management firm, announces the release of its whitepaper, „The Importance of Clinical Trials in Cancer Care.“ This report highlights the critical role of clinical trials in advancing cancer treatment, improving patient outcomes, and lowering costs for employers. Clinical trials are crucial for testing the safety and efficacy of new medical treatments and interventions. However, access to these trials has often been hindered by the clinical and scientific complexity of identifying and prioritizing appropriate trials. Other challenges impacting enrollment include geographic location, socioeconomic status, and lack of awareness. According to recent estimates, just 7% of patients with cancer in the U.S. have participated in a clinical trial. PHM’s trial enrollment rate is 25%, demonstrating the potential for significantly higher participation in clinical trials when care management support is provided.

BioArctic AB’s (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that Leqembi® (generic name: lecanemab) has been approved for treatment of Alzheimer’s disease (AD) in Israel. Treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Israel is the sixth territory to approve Leqembi following the US, Japan, China, South Korea and Hong Kong. Leqembi’s approval in Israel is based on the large global Phase 3 Clarity AD study. In the Clarity AD study, Leqembi met its primary endpoint and all key secondary endpoints with statistically significant results.[1] Leqembi selectively binds to soluble amyloid-beta (A?) aggregates (protofibrils[2]), as well as insoluble A? aggregates (fibrils) which are a major component of A? plaques in AD, thereby reducing both A? protofibrils and… 

Health Canada has granted a Notice of Compliance (NOC) for Tagrisso® (osimertinib) in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.1 The approval of Tagrisso in combination with chemotherapy was granted based on the results from the FLAURA2 Phase III clinical trial, which was published in the New England Journal of Medicine in November 2023.2 Tagrisso with the addition of chemotherapy reduced the risk of disease progression or death by 38% compared to Tagrisso monotherapy which is the 1st-line global standard of care (hazard ratio [HR] 0.62; 95% confidence interval [CI] 0.49, 0.79; p<0.0001). Median progression-free survival (PFS) by investigator assessment was 25.5 months for patients treated with…